Brickell Biotech (NASDAQ:BBI) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Brickell Biotech (NASDAQ:BBIGet Rating) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. It is focused on developing prescription therapeutics for treatment of skin diseases. The company’s pipeline consists of therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. Its products include Prozac(R), Gemzar(R), Cialis(R), Evista(R), Talz(R), Humulin(R), Cymbalta(R), Dysport(R), Juvederm(R) and Kybella(R). Brickell Biotech Inc., formerly known as Vical Incorporated, is based in San Diego, United States. “

BBI has been the topic of several other research reports. William Blair initiated coverage on Brickell Biotech in a report on Tuesday, March 8th. They set an outperform rating on the stock. Lake Street Capital downgraded Brickell Biotech from a buy rating to a hold rating in a research report on Friday, May 13th. Finally, HC Wainwright initiated coverage on Brickell Biotech in a research report on Tuesday, January 18th. They set a buy rating and a $2.00 price objective for the company.

Shares of NASDAQ:BBI opened at $0.16 on Wednesday. Brickell Biotech has a 1 year low of $0.16 and a 1 year high of $1.04. The firm has a market capitalization of $19.46 million, a price-to-earnings ratio of -0.35 and a beta of 0.12. The business’s 50 day moving average price is $0.25 and its 200-day moving average price is $0.26.

Brickell Biotech (NASDAQ:BBIGet Rating) last announced its earnings results on Thursday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Brickell Biotech had a negative net margin of 8,325.47% and a negative return on equity of 191.55%. During the same period in the previous year, the business posted ($0.15) EPS. As a group, analysts forecast that Brickell Biotech will post -0.21 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BBI. BlackRock Inc. increased its holdings in Brickell Biotech by 69.2% during the 3rd quarter. BlackRock Inc. now owns 63,544 shares of the company’s stock worth $46,000 after purchasing an additional 25,985 shares during the period. Morgan Stanley increased its holdings in shares of Brickell Biotech by 142.0% in the 1st quarter. Morgan Stanley now owns 75,404 shares of the company’s stock valued at $82,000 after acquiring an additional 44,248 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Brickell Biotech in the 2nd quarter valued at about $76,000. Two Sigma Investments LP increased its holdings in shares of Brickell Biotech by 277.2% in the 3rd quarter. Two Sigma Investments LP now owns 90,085 shares of the company’s stock valued at $65,000 after acquiring an additional 66,200 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Brickell Biotech in the 4th quarter valued at about $51,000. 14.99% of the stock is owned by hedge funds and other institutional investors.

Brickell Biotech Company Profile (Get Rating)

Brickell Biotech, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

Further Reading

Get a free copy of the Zacks research report on Brickell Biotech (BBI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brickell Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brickell Biotech and related companies with MarketBeat.com's FREE daily email newsletter.